LifeStance Health director Teresa DeLuca sells $249,993 in shares

On August 13, 2026, LifeStance Health Group director Teresa DeLuca sold 20,441 shares of the company's common stock, totaling $249,993. The shares were traded at $12.23 each, coming as the stock approached its 52-week high of $12.76 after a 123% increase over the past year. DeLuca's stake is now reduced to 104,593 shares. Although she sold shares, LifeStance Health management has been actively buying back company stock.

Despite this, the stock is currently considered slightly overvalued by InvestingPro, which provides 16 additional tips and Pro Research Reports for an additional fee. LifeStance Health recently surpassed analyst expectations for the second quarter of 2026, reporting adjusted earnings of $0.06 per share and revenue of $435.35 million, exceeding forecasts of $0.03 per share and $414.38 million.

The company also raised its full-year outlook due to a 26% revenue increase, a 94% rise in adjusted EBITDA, and positive net income. Growth was driven by increased visit volumes and higher revenue per visit, with adjusted EBITDA reaching $66 million, boosting the margin from 9.8% to 15.2%. Management credited productivity gains, payer contracting, and specialty services for this success.